On June 18th – 22nd, ASBM exhibited at the Biotechnology Innovation Organization (BIO) International Conference in San Diego, CA.
ASBM was represented in the Australian Pavilion by Advisory Board Chair Philip Schneider and Steering Committee Member Andrew Spiegel, Executive Director of the Global Colon Cancer Alliance. Dean Schneider and Mr. Spiegel distributed summaries of survey findings from ASBM’s survey of Australian biologic prescribers.
Both met with Australian regulators and government officials to discuss the findings, and how to address physician concerns to improve biosimilar uptake in Australia.
The issue of non-medical switching, a contentious issue within Australia, was also discussed widely in the Pavilion.
Mr. Spiegel was also invited to speak at the bilateral meeting with the South Africans to discuss emerging issues on biologics and biosimilar issues at the BIO Convention.